Cost Is the Biggest Barrier to Repatha Adherence — Here's How to Help

As a prescriber, you already know that Repatha (Evolocumab) can produce dramatic LDL reductions for your highest-risk patients. But you also know that the conversation about cost comes up almost every time you write the prescription. For many patients, the sticker price of a PCSK9 inhibitor — even after insurance — can be the difference between adherence and abandonment.

This guide is designed for cardiologists, lipidologists, endocrinologists, and primary care providers who prescribe Repatha. It covers what your patients are actually paying, the manufacturer savings programs available, alternative cost-reduction strategies, and how to build cost conversations into your clinical workflow.

What Patients Are Actually Paying

Understanding the financial landscape helps you anticipate barriers before they derail treatment:

• Retail cash price: $500–$700 per month for the 140 mg prefilled syringe or SureClick autoinjector
• Annual list price: Approximately $5,850/year (after Amgen's 2018 net price reduction)
• Commercial insurance with copay card: As low as $5/month for eligible patients
• Commercial insurance without copay card: Specialty tier copays can range from $50–$300+/month depending on plan design
• Medicare Part D: Covered with prior authorization. Patients may face significant cost-sharing during the coverage gap (donut hole), though this has improved with recent legislation
• Uninsured: Full cash price unless eligible for patient assistance

The critical takeaway: the difference between a patient paying $5/month and $500/month often comes down to whether the right savings program was activated at the point of prescribing.

Manufacturer Savings Programs

Repatha Copay Card (Commercial Insurance)

Amgen's copay assistance program is the most impactful cost-reduction tool for commercially insured patients:

• Eligible patients pay as little as $5 per month
• Available to patients with commercial (private) insurance
• Not available for patients on Medicare, Medicaid, Tricare, or other government insurance
• Enrollment available at repatha.com or by calling 1-844-REPATHA
• Maximum annual benefit varies; verify current terms at enrollment

Best practice: Have your staff initiate copay card enrollment at the time of prescribing, before the prescription reaches the pharmacy. This prevents patients from experiencing sticker shock at the pharmacy counter and abandoning the fill.

Amgen Safety Net Foundation (Uninsured/Underinsured)

For patients who lack adequate insurance coverage:

• Provides free Repatha to qualifying patients
• Eligibility: Household income at or below 400% of the federal poverty level
• Requires physician attestation and income documentation
• Application available through Amgen or by calling the foundation directly

Amgen FIRST STEP Program

For patients experiencing access delays (prior authorization processing, insurance appeals):

• Provides temporary free medication while insurance issues are resolved
• Prevents gaps in therapy during the prior authorization process
• Particularly useful for patients transitioning between insurance plans

Proactively enrolling patients in FIRST STEP at the time of prescribing can prevent treatment gaps that might otherwise lead to discontinuation.

Coupon and Discount Cards

Beyond the manufacturer's programs, several third-party platforms may offer pricing for patients paying cash or with high-deductible plans:

• GoodRx — Shows pricing at various pharmacies and may offer coupons, though savings on specialty biologics are typically more limited than for small-molecule generics
• RxSaver — Similar pricing comparison tool
• SingleCare — May offer discounted pricing at select pharmacies

For most commercially insured patients, the manufacturer copay card will provide better savings than third-party discount cards. However, these tools can be useful for cash-pay patients who don't qualify for the Amgen Safety Net Foundation.

For a comprehensive patient-facing guide to all savings options, you can direct patients to our article on how to save money on Repatha.

Generic Alternatives and Therapeutic Substitution

There is currently no generic or biosimilar for Repatha available in the United States. However, several therapeutic alternatives exist within and adjacent to the PCSK9 inhibitor class that may offer cost advantages for certain patients:

Within the PCSK9 Inhibitor Class

• Praluent (Alirocumab) — Another PCSK9 inhibitor monoclonal antibody with similar efficacy and mechanism. Pricing and insurance coverage may differ, so switching between the two can sometimes resolve a cost or access issue.
• Leqvio (Inclisiran) — An siRNA-based PCSK9 inhibitor administered by a healthcare provider every 6 months. The in-office administration model changes the cost and adherence dynamic. May be covered differently than self-administered PCSK9 inhibitors.

Alternative LDL-Lowering Agents

• Nexletol (Bempedoic Acid) — Oral ACL inhibitor, available as a daily pill. Good for statin-intolerant patients. Less LDL reduction than PCSK9 inhibitors but significantly cheaper.
• Nexlizet (Bempedoic Acid + Ezetimibe) — Combination pill that may provide meaningful additional LDL lowering for patients who can't access or afford a PCSK9 inhibitor.
• Zetia (Ezetimibe) — Available as a low-cost generic. Modest LDL reduction (15-20%) but widely accessible. Often already part of the patient's regimen before PCSK9 inhibitor consideration.

Therapeutic substitution decisions should be based on clinical appropriateness — the patient's cardiovascular risk, LDL target, statin tolerance, and previous medication trials. For more on alternatives, see our alternatives to Repatha guide.

Building Cost Conversations Into Your Workflow

Cost-related non-adherence is a clinical problem, not just an administrative one. Here are practical strategies for integrating cost management into your prescribing workflow:

At the Point of Prescribing

• Run a benefits investigation before writing the prescription. Many specialty pharmacy hubs (including Amgen's) can verify coverage and estimate patient cost before the first fill.
• Enroll in copay assistance proactively. Don't wait for the patient to encounter a high copay — activate the manufacturer savings card before the prescription reaches the pharmacy.
• Set expectations. Tell patients: "This medication has a high list price, but there are programs that can bring your cost down to $5 a month. My staff will help you enroll."

During Follow-Up Visits

• Ask about cost at every visit. A simple question — "Are you having any trouble affording your medications?" — can uncover issues before they lead to missed doses.
• Monitor adherence. If a patient is refilling less frequently than prescribed, cost may be the reason. Specialty pharmacy reports can help identify this pattern.
• Reassess annually. Insurance plan changes, copay card renewals, and program eligibility can shift year to year. Check in on financial access as part of your annual review.

For Your Staff

• Train your medical assistants and care coordinators on copay card enrollment and prior authorization requirements for PCSK9 inhibitors
• Create a reference sheet with enrollment links and phone numbers for Amgen programs
• Track prior authorization approval rates and denial reasons to streamline future submissions

For support managing Repatha access and availability challenges across your practice, explore Medfinder for Providers.

Final Thoughts

Repatha is a clinically powerful medication that too many patients can't afford to take consistently. The savings programs exist — the challenge is connecting patients to them reliably and early. By building cost conversations and program enrollment into your prescribing workflow, you can dramatically improve adherence and outcomes.

The bottom line: when you write a Repatha prescription, don't just send it to the pharmacy. Send the copay card with it. Enroll the patient in FIRST STEP. Document the prior authorization proactively. These steps take minutes but can make the difference between a patient who takes their medication and one who abandons it at the pharmacy counter.

Related resources for providers: Repatha shortage update for providers | How to help patients find Repatha in stock